Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus BETA VAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus BETA VAL.
ARAZLO vs BETA-VAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Betamethasone is a corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating gene expression.
Topical: Apply 0.045% gel once daily to affected areas of the face.
0.1 mg topical cream applied to affected area twice daily
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function. In patients with creatinine clearance <30 mL/min, half-life may extend to 30-40 hours, requiring dose adjustment.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Renal excretion of unchanged drug accounts for 60-80% of the dose. Hepatic metabolism produces inactive metabolites, with approximately 15-25% eliminated via bile and feces. A small fraction (5-10%) is excreted unchanged in feces.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid